The application of serum biomarkers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), CA19-9, CA724, and CA242 in colorectal, ovarian, and pancreatic cancer has been widely reported in the literature and used in the clinic (6–8). Here, CEACAM5 is linked to familial pancreatic carcinoma.